Silence Therapeutics (NASDAQ:SLN) Issues Earnings Results

Silence Therapeutics (NASDAQ:SLN) posted its earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13), FiscalAI reports. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.

Silence Therapeutics Stock Performance

Shares of Silence Therapeutics stock opened at $11.95 on Monday. The business has a 50-day moving average price of $9.31 and a two-hundred day moving average price of $7.18. Silence Therapeutics has a 1-year low of $4.19 and a 1-year high of $12.31. The company has a market cap of $564.52 million, a P/E ratio of -7.52 and a beta of 1.39.

Institutional Investors Weigh In On Silence Therapeutics

Several large investors have recently added to or reduced their stakes in SLN. XTX Topco Ltd acquired a new position in Silence Therapeutics in the fourth quarter valued at approximately $71,000. Massar Capital Management LP bought a new stake in shares of Silence Therapeutics in the 2nd quarter valued at $115,000. Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $112,000. ADAR1 Capital Management LLC lifted its position in shares of Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Silence Therapeutics during the 4th quarter valued at $177,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Analyst Ratings Changes

SLN has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald began coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.